Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma.

Abstract

Recurrent gain on chromosome 3q26 encompassing the gene locus for the transcription factor SOX2 is a frequent event in human squamous cell carcinoma, including head and neck squamous cell carcinoma (HNSCC). Numerous studies demonstrated that SOX2 expression and function is related to distinct aspects of tumor cell pathophysiology. However, the underlying molecular mechanisms are not well understood, and the correlation between SOX2 expression and clinical outcome revealed conflicting data. Transcriptional profiling after silencing of SOX2 expression in a HNSCC cell line identified a set of up-regulated genes related to cell motility (e.g. VIM, FN1, CDH2). The inverse regulation of SOX2 and aforementioned genes was validated in 18 independent HNSCC cell lines from different anatomical sites. The inhibition of cell migration and invasion by SOX2 was confirmed by constant or conditional gene silencing and accelerated motility of HNSCC cells after SOX2 silencing was partially reverted by down-regulation of vimentin. In a retrospective study, SOX2 expression was determined by immunohistochemical staining on tissue microarrays containing primary tumor specimens of two independent HNSCC patient cohorts. Low SOX2 expression was found in 19.3% and 44.9% of primary tumor specimens, respectively. Univariate analysis demonstrated a statistically significant correlation between low SOX2 protein levels and reduced progression-free survival (Cohort I 51 vs. 16 months; Cohort II 33 vs. 12 months) and overall survival (Cohort I 150 vs. 37 months; Cohort II 33 vs. 16 months). Multivariate Cox proportional hazard model analysis confirmed that low SOX2 expression serves as an independent prognostic marker for HNSCC patients. We conclude that SOX2 inhibits tumor cell motility in HNSCC cells and that low SOX2 expression serves as a prognosticator to identify HNSCC patients at high risk for treatment failure.

• Authors: Pilar Bayo, Adriana Jou, Albrecht Stenzinger, Chunxuan Shao, Madeleine Gross, Alexandra Jensen, Niels Grabe, Christel Herold Mende, Pantelis Varvaki Rados, Juergen Debus, Wilko Weichert, Peter K Plinkert, Peter Lichter, Kolja Freier, Jochen Hess
• Journal: Molecular oncology (Mol Oncol) Vol. 9 Issue 8 Pg. 1704-19 (Oct 2015) ISSN: 1878-0261 [Electronic] United States
• PMID: 26040981 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Chemical References

• SOX2 protein, human
• SOXB1 Transcription Factors
• Vimentin

Topics

• Adult
• Aged
• Aged, 80 and over
• Carcinoma, Squamous Cell (genetics, mortality, pathology, therapy)
• Cell Line, Tumor
• Cell Movement (genetics)
• Down-Regulation
• Female
• Gene Deletion
• Gene Expression Regulation, Neoplastic
• Head and Neck Neoplasms (genetics, mortality, pathology, therapy)
• Humans
• Male
• Middle Aged
• Retrospective Studies
• Risk Factors
• SOXB1 Transcription Factors (genetics, metabolism)
• Squamous Cell Carcinoma of Head and Neck
• Survival Analysis
• Vimentin (genetics, metabolism)